Talk:N-Methyl-Cyclazodone: Difference between revisions
>Carphknight Finishing NMC's article a bit further |
>Carphknight m 4 |
||
Line 4: | Line 4: | ||
Unlike [[cyclazodone]], '''N-methyl-cyclazodone''' has little to no history of use and only recently emerged as a study aid. Its non-clinical use has only found recent attention as a [[research chemical]] study aid or atypical [[antidepressant]]. It should be noted that the lack of pharmacological data and extremely limited history of human usage pose considerable concern regarding its long-term use as a substitute for prescription stimulants or [[antidepressants]]. Similar to [[methamphetamine]], this substance is reported to possess an usually long duration, it is therefore recommended to take one's dose in the morning and avoid redosing. | Unlike [[cyclazodone]], '''N-methyl-cyclazodone''' has little to no history of use and only recently emerged as a study aid. Its non-clinical use has only found recent attention as a [[research chemical]] study aid or atypical [[antidepressant]]. It should be noted that the lack of pharmacological data and extremely limited history of human usage pose considerable concern regarding its long-term use as a substitute for prescription stimulants or [[antidepressants]]. Similar to [[methamphetamine]], this substance is reported to possess an usually long duration, it is therefore recommended to take one's dose in the morning and avoid redosing. | ||
[[Subjective effects]] include [[stimulation]], [[focus enhancement]], [[stamina enhancement]], [[increased blood pressure]], and mild [[euphoria]]. Some anecdotal reports suggest that '''N-methyl-cyclazodone''' and its parent compound [[cyclazodone]] may have nootropic properties similar to central nervous system stimulants such as [[methylphenidate]] and [[amphetamine]]. | |||
One of its parent compounds, [[thozalinone]], has been used as an [[antidepressant]] in europe<ref>{{cite journal | vauthors = Gallant DM, Bishop MP, Scrignar CB, Hornsby L, Moore B, Inturrisi BB | title = A double-blind study of thozalinone (C1 39,808) in depressed outpatients | journal = Current Therapeutic Research, Clinical and Experimental | volume = 8 | issue = 12 | pages = 621–2 | date = December 1966 | pmid = 4962734 }}</ref>, which may be due to its serotonin-releasing properties. | One of its parent compounds, [[thozalinone]], has been used as an [[antidepressant]] in europe<ref>{{cite journal | vauthors = Gallant DM, Bishop MP, Scrignar CB, Hornsby L, Moore B, Inturrisi BB | title = A double-blind study of thozalinone (C1 39,808) in depressed outpatients | journal = Current Therapeutic Research, Clinical and Experimental | volume = 8 | issue = 12 | pages = 621–2 | date = December 1966 | pmid = 4962734 }}</ref>, which may be due to its serotonin-releasing properties. | ||
'''N-methyl-cyclazodone''' has no documented history of recreational human usage before it appeared on the online research chemical market in 2017. Based on related compounds, it is speculated that it likely possesses hepatotoxic and other not-yet-known toxic properties. | '''N-methyl-cyclazodone''' has no documented history of recreational human usage before it appeared on the online research chemical market in 2017. Based on related compounds, it is speculated that it likely possesses hepatotoxic and other not-yet-known toxic properties. | ||
Line 35: | Line 35: | ||
*'''[[Effect::Stamina enhancement]]''' | *'''[[Effect::Stamina enhancement]]''' | ||
*'''[[Effect::Abnormal heartbeat]]'''{{citation needed}} | *'''[[Effect::Abnormal heartbeat]]'''{{citation needed}} | ||
*'''[[Effect::Increased heart rate]]'''{{citation needed}} - | *'''[[Effect::Increased heart rate]]'''{{citation needed}} - This effect is reported to be not as strong with N-methyl-cyclazodone as with [[cyclazodone]] | ||
*'''[[Effect::Increased blood pressure]]'''{{citation needed}} | *'''[[Effect::Increased blood pressure]]'''{{citation needed}} | ||
*'''[[Effect::Appetite suppression]]''' | *'''[[Effect::Appetite suppression]]''' | ||
Line 48: | Line 48: | ||
*'''[[Effect::Pupil dilation]]''' - This effect is typically experienced only at higher dosages and is more prominent on the comedown. | *'''[[Effect::Pupil dilation]]''' - This effect is typically experienced only at higher dosages and is more prominent on the comedown. | ||
*'''[[Effect::Stomach cramps]]''' | *'''[[Effect::Stomach cramps]]''' | ||
*'''[[Effect::Teeth grinding]]''' - This component is reported to be less intense compared to[[MDMA]], and only prominent when dosing for prolonged periods of time. | *'''[[Effect::Teeth grinding]]''' - This component is reported to be less intense compared to [[MDMA]], and only prominent when dosing for prolonged periods of time. | ||
*'''[[Effect::Temporary erectile dysfunction]]''' | *'''[[Effect::Temporary erectile dysfunction]]''' | ||
*'''[[Effect::Vasoconstriction]]'''{{citation needed}} | *'''[[Effect::Vasoconstriction]]'''{{citation needed}} | ||
Line 75: | Line 75: | ||
*'''[[Effect::Delusion]]''' | *'''[[Effect::Delusion]]''' | ||
*'''[[Effect::Disinhibition]]''' | *'''[[Effect::Disinhibition]]''' | ||
*'''[[Effect::Ego inflation]]''' | *'''[[Effect::Ego inflation]]''' | ||
*'''[[Effect::Emotion suppression]]''' | *'''[[Effect::Emotion suppression]]''' | ||
*'''[[Effect::Focus enhancement]]''' | *'''[[Effect::Focus enhancement]]''' |